All In Biotech

Drug Trial Radar · NCT03733249

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

187

Actual

Start

Jan 2017

Primary completion

Jun 30, 2020

Study completion Apr 14, 2023

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.

Conditions

  • Acute Lymphoblastic Leukemia
  • Leukemia, Acute Myeloid (AML), Child
  • Lymphoma, Non-Hodgkin
  • Myelodysplastic Syndromes
  • Primary Immunodeficiency
  • Anemia, Aplastic
  • Hemoglobinopathies
  • Cytopenia
  • Fanconi Anemia
  • Diamond Blackfan Anemia
  • Thalassemia
  • Anemia, Sickle Cell

Interventions

  • RimiducidDrug

    Rimiducid is administered to treat chronic graft versus host disease

  • rivogenlecleucelBiological

    donor T-cells modified with iCasp safety switch

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 1 and 2 years after rivogenlecleucel infusion
  2. Incidence of Disease-free SurvivalTime frame: 1 and 2 years after rivogenlecleucel infusion
  3. Relapse-free SurvivalTime frame: 1 and 2 years after rivogenlecleucel infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.